Navigation Links
Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
Date:12/5/2013

INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) in three acute randomized placebo-controlled Phase III studies (LNBM, LNBQ and LNBR).

While the safety and tolerability of edivoxetine was consistent with previous studies, the efficacy results do not support a regulatory submission for adjunctive treatment in patients with Major Depressive Disorder (MDD). Data from all three studies will be disclosed in appropriate scientific forums in 2014.

In 2010, Lilly launched the Phase III program for edivoxetine – a potent and highly selective norepinephrine reuptake inhibitor – to assess the benefits and risks of edivoxetine as an add-on therapy in patients with MDD.  The Phase III program specifically focused on meeting the unmet needs of patients with major depression who had achieved only a partial response to treatment with an SSRI.  In these three trials, patients remained on SSRI treatment and additionally received either edivoxetine or placebo. 

"Lilly undertook a robust Phase III program to address a significant unmet need for people suffering from depression," said David Ricks, senior vice president, and president, Lilly Bio-Medicines. "However, the lack of efficacy compared to SSRI alone in three separate clinical trials means that Lilly will not proceed with development of edivoxetine as an add-on treatment for depression." The ongoing clinical study evaluating the long-term maintenance effect of edivoxetine will continu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zacks Industry Outlook Highlights: Merck, Pfizer, Forest Laboratories, Sanofi and Eli Lilly
2. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
3. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
4. Lilly Statement on Contribution to Indiana Biosciences Research Institute
5. Lilly Announces Significant Global Insulin Manufacturing Capacity Investments in Response to Growing Diabetes Epidemic
6. Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes
7. Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets
8. Lilly Reports Third-Quarter 2013 Results
9. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
10. Lilly Declares Fourth-Quarter 2013 Dividend
11. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... Jan. 27, 2011 Significant flooding occurred in many ... January 2011.  Thousands of residents were affected.  A disaster ... on 29 December 2010, by Premier of Queensland, Anna ... in to help their fellow citizens clean-up in the ...
... China and ROCKVILLE, Md., Jan. 26, 2011 /PRNewswire-Asia/ -- Synutra ... formula company in China and a producer, marketer and seller ... that it plans to release its financial results for the ... 2011 after market close. The Company will ...
Cached Medicine Technology:DSM Joins International Response to Flooding in Australia 2DSM Joins International Response to Flooding in Australia 3Synutra to Announce Third Quarter Fiscal 2011 Financial Results 2
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review that ... loss program ever developed. It promises to provide users the ... no wonder after all that this has become the most ... and workout fat loss program was created by Joel Marion, ... the author of this fat loss system, the method can ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... Colorado (PRWEB) October 31, 2014 The ... that this workout program was developed by Dan Long, ... become well-known as a fitness professional and life coach. ... fat and having toned muscles is not impossible , ... based on suspension training. Suspension training promises efficiency when ...
(Date:10/31/2014)... NY (PRWEB) October 31, 2014 ... the most remarkable gifts of life — building a ... matching extraordinary surrogate mothers and donors with hopeful intended ... in unforeseen circumstances. , It’s a collective aptitude of ... agencies, surrogacy lawyers, and fertility clinics that help provide ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... the prosthesis that has helped thousands of disabled worldwide to ... first centre on foreign soil . ,The Colombian government ... of the artificial limb, to set up base in the ... with a Colombia-based NGO. ,M.K. Mathur of BMVSS ...
... disease (STD) has surpassed Neisseria gonorrhea in prevalence among young ... a big menace, researchers say . ,The new ... the 1980s. It can cause inflammation of the urethra (the ... the cervix and the lining of the uterus in women, ...
... on less than 50 pence (Rs.40) a day will benefit from ... the number of children who die before their fifth birthday. ... when mothers give birth, a doctor or nurse is available to ... much better chance of survival. ,Groups at a high ...
... are weak at mathematics, reading, and writing better watch out ... research suggests that such symptoms may cause students to ... Bachmann of Chappaqua Public Schools in New York, the study ... graders, who completed Sleep Disorders Inventory for Students - Child ...
... new genetic cause for Joubert syndrome (JS), an inherited ... brainstem-the structures in the brain that coordinate movements and ... and consciousness. ,This is the fifth gene ... syndrome. Researchers at Seattle Children's Hospital Research Institute, the ...
... University of Washington and other members of an international ... genome functions . While previous studies of the human ... insight into the non-gene sequences making up the vast ... non-gene sequences are so-called "regulatory elements" that contain instructions ...
Cached Medicine News:Health News:Jaipur Foot All Set to Launch Its Centre in Columbia 2Health News:British Funds 250 Million Pounds to Reduce Child Mortality 2Health News:Students With Sleep Disorder Symptoms Score Badly in Maths 2Health News:Boffins Identify Fifth Gene Behind Joubert Syndrome 2Health News:Researchers Cracking the Human Genome Function 2Health News:Researchers Cracking the Human Genome Function 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 11 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Medicine Products: